QL1A Stock Chart & Stats
€13.98
-€0.39(-2.71%)
At close: 4:00 PM EDT
€13.98
-€0.39(-2.71%)
Day’s Range― - ―
52-Week Range€8.22 - €30.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€877.64M
Enterprise Value€3.89K
Total Cash (Recent Filing)€123.40M
Total Debt (Recent Filing)€3.08B
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 04, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.44
Shares Outstanding68,575,424
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.87Price Target Upside-7.96% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.66
Revenue Forecast (FY)€2.18B
Bulls Say, Bears Say
Bulls Say
Resilient Ex-China DemandGrowth across core franchises outside China indicates durable customer demand and geographic diversification. Broad adoption in laboratories, immunohematology, and point-of-care testing can support recurring consumables revenue despite regional volatility.
Improving Adjusted EBITDA And Operating DisciplineStrong EBITDA growth and margin expansion show that productivity initiatives and expense control are improving operating leverage. If sustained, this can strengthen earnings quality and help the company convert revenue growth into greater cash generation.
Recurring Consumables Platform With Lex ExpansionQuidelOrtho’s installed diagnostic platforms create repeat demand for tests and reagents, while Neulixa expands its respiratory offering. Successful commercialization could broaden the menu, increase utilization, and reinforce recurring consumables revenue.
Bears Say
Deep Losses And Negative Cash GenerationLarge losses and recent cash burn weaken self-funding capacity and limit flexibility for investment, debt reduction, and acquisitions. Sustained improvement in profitability and working-capital conversion is necessary before the business can reliably fund operations.
Elevated Leverage Constrains Financial FlexibilityHigh leverage relative to current operating earnings increases refinancing and execution risk while directing cash toward balance-sheet repair. It may constrain strategic investment and make the company more exposed to prolonged demand weakness or margin pressure.
China Pricing Uncertainty And Softer Respiratory DemandPotential IVD pricing changes can pressure volume, pricing, and customer purchasing behavior in China, while weaker respiratory testing reduces a key demand driver. Together, these factors create persistent revenue and mix risk over the next several quarters.
QuidelOrtho News
QL1A FAQ
What was Quidelortho Corporation’s price range in the past 12 months?
Quidelortho Corporation lowest stock price was €8.22 and its highest was €30.40 in the past 12 months.
What is Quidelortho Corporation’s market cap?
Quidelortho Corporation’s market cap is €877.64M.
When is Quidelortho Corporation’s upcoming earnings report date?
Quidelortho Corporation’s upcoming earnings report date is Nov 04, 2026 which is in 68 days.
How were Quidelortho Corporation’s earnings last quarter?
Quidelortho Corporation released its earnings results on Aug 06, 2026. The company reported €0.111 earnings per share for the quarter, beating the consensus estimate of -€0.042 by €0.153.
Is Quidelortho Corporation overvalued?
According to Wall Street analysts Quidelortho Corporation’s price is currently Overvalued.
Does Quidelortho Corporation pay dividends?
Quidelortho Corporation does not currently pay dividends.
What is Quidelortho Corporation’s EPS estimate?
Quidelortho Corporation’s EPS estimate is 0.17.
How many shares outstanding does Quidelortho Corporation have?
Quidelortho Corporation has 68,575,424 shares outstanding.
What happened to Quidelortho Corporation’s price movement after its last earnings report?
Quidelortho Corporation reported an EPS of €0.111 in its last earnings report, beating expectations of -€0.042. Following the earnings report the stock price went down -28.357%.
Which hedge fund is a major shareholder of Quidelortho Corporation?
Currently, no hedge funds are holding shares in DE:QL1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€12.87 (-7.96% Downside)
€12.87 (-7.96% Downside)
Blogger Sentiment
Neutral
DE:QL1A Sentiment 60%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
Quidelortho Corporation
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QL1A Company Deck
QL1A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all DE:QL1A earnings summariesQL1A Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€12.87
▼(-7.96% Downside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month












